Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Bio to Distribute, Support Chan Adverse Event Test in Europe

NEW YORK (GenomeWeb News) — Cambridge BioScience today said it will distribute and support Chan Test’s potassium channel assays in Europe.
 
Cleveland-based Chan Test’s assay, based on ion channels, is designed to predict cardiac events associated with non-cardiac drugs.
 
Cambridge BioScience Managing Director Mike Kerns said his company expects “significant growth” for the assay due to “the rapidly growing interest in ion channels as primary targets in areas such as pain and epilepsy research.”
 
Financial terms of the agreement were not released.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.